Plain-English translation of NCT06427343 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study tests whether giving patients with heart failure and iron deficiency higher doses of ferric derisomaltose (an iron medication given through an IV) works better than lower doses. The trial will measure how well your body can use oxygen during exercise and track your overall health over 12 months to see which dosing strategy helps you feel better and function more easily.
Iron deficiency is very common in people with heart failure and makes symptoms worse. Previous studies have shown that IV iron helps patients exercise better and feel better, but doctors aren't sure whether giving more iron is better than giving less. This trial will help answer that question so doctors can treat patients more effectively.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either higher or lower doses of iron through an IV infusion over the course of one year. At the start, you'll have an exercise test to measure how well your heart and lungs work together. Every three months, you'll have blood tests to check your iron levels, which will determine your iron dose going forward. You'll visit the clinic for IV infusions as needed based on your iron levels, with each infusion taking 15–30 minutes depending on the dose.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
China